Spero Therapeutics, Inc., was incorporated in December 2013 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company focused on identifying and developing new therapies for rare diseases and diseases with high unmet need. The company's clinical stage product candidate teipenem HBr has completed its second Phase 3 trial and has the potential to be the first oral carbapenem for the treatment of adult patients with complex urinary tract infections caused by certain microorganisms, including pyelonephritis. 

Spero Therapeutics has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4), approving a grant of 102,000 restricted stock unit awards and 67,600 stock options to new employees. The stock options and RSUs will vest as to 25% on September 1, 2027, and the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment with Spero. The RSUs will vest in four equal annual installments beginning on September 1, 2027, subject to the same condition.

Spero Therapeutics

Spero Therapeutics Grants 102,000 RSUs and 67,600 Stock Options to New Employees

Spero Therapeutics, Inc. (NASDAQ: SPRO), a clinical-stage biopharmaceutical company focused on developing next-generation immunology and inflammation therapies, has <a href="https://www.google.com/goto?url=CAESiQEB6zswFcz_mF3Cgl2Yus3oiaveUnOE2wbLWP9d20fGTgidlca94PPbIP25s8HVV4xYz31i9-1auidXF6_jNJBKSDzVpXDRcUc_eY8ybkhAWHnmnQbNda6B2sJ3T692L8rsFdSoMP3ooBK4CXkJ-bkgtuie_AM2EFS9aiSean7bMYonvwvnJo2n8g">filed with the U.S. Securities</a> and Exchange Commission (SEC) to offer up to $300 million in securities, according to a recent SEC filing. The company has not disclosed the specific terms of the offering, including the type of securities, pricing, or intended use of proceeds. However, such a move could provide additional capital to support its ongoing research and development efforts, particularly for its <a href="https://www.google.com/goto?url=CAESWgHrOzAVYtvbTE0pLEb30siH_0OxyLuo0YamXGs-kpO_mAeGfvL5RBOGZC1kS0AZ-XYQU9UEBvtZHSOgOESUV0gtP2N6jq1hQH10BigDn-e_JeQc98C8ckVPxA">lead program, SP001</a>, a novel Fc-silent anti-CD40L monoclonal antibody being advanced in IgG4-related disease.Spero Therapeutics, founded in 2013 and <a href="https://www.google.com/goto?url=CAESWgHrOzAVYtvbTE0pLEb30siH_0OxyLuo0YamXGs-kpO_mAeGfvL5RBOGZC1kS0AZ-XYQU9UEBvtZHSOgOESUV0gtP2N6jq1hQH10BigDn-e_JeQc98C8ckVPxA">listed on the NASDAQ</a> since November 2, 2017, operates from its headquarters in Cambridge, Massachusetts. The company does not currently pay dividends and has <a href="https://www.google.com/goto?url=CAESWgHrOzAVYtvbTE0pLEb30siH_0OxyLuo0YamXGs-kpO_mAeGfvL5RBOGZC1kS0AZ-XYQU9UEBvtZHSOgOESUV0gtP2N6jq1hQH10BigDn-e_JeQc98C8ckVPxA">no Dividend Reinvestment Plan</a> in place. Investors seeking updates on the offering or additional company news can <a href="https://www.google.com/goto?url=CAESWgHrOzAVYtvbTE0pLEb30siH_0OxyLuo0YamXGs-kpO_mAeGfvL5RBOGZC1kS0AZ-XYQU9UEBvtZHSOgOESUV0gtP2N6jq1hQH10BigDn-e_JeQc98C8ckVPxA">contact Spero’s investor relations</a> team at IR@sperotherapeutics.com. All SEC filings, including the details of this offering, are <a href="https://www.google.com/goto?url=CAESWgHrOzAVYtvbTE0pLEb30siH_0OxyLuo0YamXGs-kpO_mAeGfvL5RBOGZC1kS0AZ-XYQU9UEBvtZHSOgOESUV0gtP2N6jq1hQH10BigDn-e_JeQc98C8ckVPxA">available for review</a> on the company’s investor relations website.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d0d69150d571001.png" alt="Spero Therapeutics - May offer up to $300 mln in securities - SEC filing">

Spero Therapeutics - May offer up to $300 mln in securities - SEC filing

Innovent Biologics (HK:1801) reported strong first-half 2026 financial results, with total revenue rising 44.8% year on year to RMB8.62 billion and product revenue increasing 56.7% to RMB8.20 billion. The performance was driven by the company’s dual-engine growth strategy, combining a broad biomedicine portfolio with <a href="https://www.tipranks.com/news/company-announcements/innovent-biologics-delivers-strong-first-half-2026-profit-and-revenue-surge">accelerated adoption of oncology drugs</a> included in China’s National Reimbursement Drug List. Gross profit increased 43.0% to RMB7.32 billion, while IFRS net profit rose 50.2% to RMB1.25 billion and <a href="https://www.tipranks.com/news/company-announcements/innovent-biologics-delivers-strong-first-half-2026-profit-and-revenue-surge">non-IFRS net profit climbed 40.5%</a> to RMB1.70 billion. To provide further insights into these results, Innovent will host its 2026 Interim Results Call on Tuesday, August 25, 2026, from 8:00-9:00 PM China/Singapore time (8:00-9:00 AM EDT). The call will feature CEO Dr. Michael Yu and senior leadership, moderated by <a href="https://www.linkedin.com/posts/innovent-biologics_innovent-will-host-its-2026-interim-results-activity-7495050899522826240-q9xT">Dr. Yang Huang, China Healthcare Analyst</a> at J.P. Morgan. In addition, Innovent recently entered an <a href="https://www.biospace.com/press-releases/spero-therapeutics-announces-second-quarter-2026-operating-results-and-provides-business-update">exclusive license agreement with Spero</a> Therapeutics for SP001, a Phase 2-ready anti-CD40L antibody for immune-mediated diseases. The collaboration underscores Innovent’s strategic focus on expanding its oncology and immunology pipeline.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d08f7a015d71001.png" alt="Innovent announces 2026 interim results and business updates">

Innovent announces 2026 interim results and business updates

Spero Therapeutics has outlined a cash runway into the second half of 2029 following a $105M royalty financing. In the last 90 days, the company achieved four major milestones, including FDA approval of Utebzi, in-licensing of SP001, repositioning its pipeline to focus on immune-mediated diseases, and hiring new employees. The financing will support the company's operations and help it achieve its strategic goals.

Spero Secures $105M Financing, Extends Cash Runway to 2029

Spero Therapeutics will report Q2 2026 financial results and provide a business update on August 12, 2026. The clinical-stage biopharmaceutical company is focused on next-generation medicines in immunology and inflammation. Management will host a conference call and live audio webcast at 5:00 pm EDT to discuss the results and update the pipeline. The archived webcast will be available for 30 days following the call.

SPRO News